Zoetis (ZTS) Drops on Report that Arthritis Drugs May
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ZTS Investors with Substantial Losses and Persons with Knowledge Who May Be Able to Assist...
Source: globenewswire.com
Zoeti Librela News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Zoeti Librela. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Zoeti Librela Today - Breaking & Trending Today
Antitrust in focus March 2024 | Allen & Overy LLP
This newsletter is a summary of the antitrust developments we think are most interesting to your business. Thomas Masterman, partner based in London, is our editor this month. He has...
Source: jdsupra.com
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine
The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a…
Source: biztoc.com
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine - Zoetis (NYSE:ZTS)
The European Commission launches probe into Zoetis over alleged market interference in dog pain medication launch. Focus on Zoetis' Librela monoclonal antibody for osteoarthritis pain relief in dogs raises antitrust concerns.
Source: benzinga.com
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine
The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs. Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs. The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs. The European Commission said that Zoetis, while working on
Source: yahoo.com